ClinicalTrials.gg
CompletedNCT03332771SOTA-GLIMUpdated May 11, 2021Results posted

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

A Phase 3 interventional study of Sotagliflozin (SAR439954) and Glimepiride in Type 2 Diabetes Mellitus, sponsored by Lexicon Pharmaceuticals. Completed at 142 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by Lexicon Pharmaceuticals · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
954
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. sotagliflozin · Diabetes Mellitus, Type 2.

Enrollment
3rd of 28
954 · median 208
Started
2017
with 8 others
Phase 3
13 of 28
none open now
Registered
17th of 28
by date
Lead sponsor
17 of 28
Lexicon Pharmaceuticals

Among the 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is one of 9 that started in 2017, is one of 13 in phase 3, and was the 17th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sotagliflozin

sotagliflozin: first FDA approval 2023 (INPEFA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing sotagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the non-inferiority of Sotagliflozin 400 milligrams (mg) compared to Glimepiride on hemoglobin A1c (HbA1c) reduction at Week 52 in participants with Type 2 Diabetes (T2D) who have inadequate glycemic control with metformin.

Secondary Objectives:

To demonstrate the superiority of Sotagliflozin 400 mg compared to Glimepiride on change in body weight, systolic blood pressure (SBP) in participants with baseline SBP ≥130 millimeter of mercury (mmHg), SBP in all participants, and proportion of participants with at least 1 documented symptomatic hypoglycemic event (≤70 milligrams per deciliter [mg/dL]).

  • To demonstrate the superiority of Sotagliflozin 400 mg compared to placebo on change in HbA1c, body weight, SBP in participants with baseline SBP ≥130 mmHg, SBP in all participants.
  • To demonstrate the superiority of Sotagliflozin 200 mg compared to placebo on change in HbA1c.
  • To demonstrate the non-inferiority of Sotagliflozin 400 mg compared to Glimepiride on change in HbA1c.
  • To demonstrate the superiority of Sotagliflozin 400 mg compared to Glimepiride on change in HbA1c.
  • To evaluate the safety and tolerability of Sotagliflozin compared to Glimepiride and placebo.
Read the detailed description

Up to 58 weeks, including a Screening Period consisting of a Screening phase of up to 2 weeks, a 2-week single-blind placebo Run-in phase, a 52-week double-blind Treatment Period, and a 2-week post-treatment Follow-up period to collect safety information.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with Type 2 Diabetes (T2D) treated with metformin at a stable dose ≥1500 milligrams per day (mg/day) or maximum tolerated dose (documented) for at least 12 weeks prior to Screening Visit; in case of documented lack of tolerance, metformin dose \<1500 mg/day is acceptable, and the dose should be stable for at least 12 weeks prior to Screening Visit.
  • Participants has given written to participate in the study in accordance with local regulations.

Exclusion criteria

Exclusion criteria:

  • Age \<18 years at the Screening Visit or \<legal age of majority, whichever is greater.
  • Type 1 diabetes mellitus.
  • , HbA1c \<7.0% or HbA1c >10% at Screening.
  • Fasting Plasma Glucose (FPG) >15 millimoles per liter (mmol/L) (>270 milligram per deciliter [mg/dL]) measured by the central laboratory at Screening (Visit 1) and confirmed by a repeat test (>15 mmol/L [>270 mg/dL]) before randomization.
  • ≤20 or >45 kilogram per meter square (kg/m\^2) at Screening.
  • Pregnant (confirmed by pregnancy test at the Screening) or breast-feeding women.
  • Women of (WOCBP) not willing to use highly effective method(s) of during the study treatment period and the follow-up period, or who are unwilling or unable to be tested for pregnancy (see Appendix A) during the study.
  • Previous use of any antidiabetic drug other than Metformin within 12 weeks preceding the Screening Visit.
  • Use of a selective Sodium-glucose co-transporter-2 (SGLT2) inhibitor (e.g., Canagliflozin, Dapagliflozin, or Empagliflozin) within 3 months prior to the Screening visit.
  • Use of systemic (excluding topical, or ophthalmic application, intra-articular, nasal spray or inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening Visit.
  • Previous insulin use >1 month (at any time, except for treatment of gestational diabetes).
  • History of prior gastric surgical procedure, including gastric banding, or inflammatory bowel disease within 3 years prior to the Screening Visit.
  • Difficulty swallowing such that the participants cannot take the medicinal product (IMP).
  • History of diabetic ketoacidosis or nonketotic hyperosmolar coma within 12 weeks prior to the Screening Visit.
  • Mean of 3 separate blood pressure measurements >180 millimeter of mercury (mmHg) (SBP) or >100 mmHg (DBP).
  • History of hypertensive emergency within 12 weeks prior to Screening.
  • Participants who have previously been randomized in any clinical trial of Sotagliflozin/LX4211.
  • Participants with severe renal disease as defined by an estimated (eGFR) of \<30 milliliter per minute per meter square (mL/min/1.73 m\^2) at Screening, based on the 4 variable Modification of Diet in Renal Disease (MDRD) equation (or according to the renal function restrictions of metformin use defined in the local approved label).
  • Participants with severe anemia, severe cardiovascular (including congestive heart failure IV), respiratory, hepatic, neurological, psychiatric, or active malignant tumor or other major systemic disease that, according to Investigator, will preclude their safe participation in this study, or will make implementation of the protocol or interpretation of the study results difficult.
  • and/or alanine aminotransferase: >3 times the laboratory range (ULN).
  • Total : >1.5 times ULN (except in case of Gilbert's syndrome).
  • Participants who have taken other investigational drugs within 12 weeks or 5 half-lives from Screening whichever is longer.
  • Participants unwilling or unable to perform self-monitoring blood glucose (SMBG), complete the participant diary, or comply with study visits and other study procedures as required per protocol.
  • Participants with to glimepiride as per local labelling.
  • Participants with contraindication to metformin as per local labelling.

The above information is not intended to contain all considerations relevant to a Participants potential participation in a clinical trial.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
954 participants (actual)

Study arms

  • Experimental
    Sotagliflozin 400 mg

    Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.

    Drug: Sotagliflozin (SAR439954) · Drug: Metformin · Drug: Placebo

  • Experimental
    Sotagliflozin 200 mg

    Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.

    Drug: Sotagliflozin (SAR439954) · Drug: Metformin · Drug: Placebo

  • Active comparator
    Glimepiride

    Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.

    Drug: Glimepiride · Drug: Metformin · Drug: Placebo

  • Placebo comparator
    Placebo

    Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.

    Drug: Metformin · Drug: Placebo

Interventions

  • DrugSotagliflozinStudies of SotagliflozinSotagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pharmaceutical form: tablet Route of administration: oral

  • Pharmaceutical form: capsule Route of administration: oral

  • Pharmaceutical form: tablet Route of administration: oral

  • DrugPlacebo

    Pharmaceutical form: tablet Route of administration: oral

  • DrugPlacebo

    Pharmaceutical form: capsule Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c at Week 52

    An analysis of covariance (ANCOVA) model was used for the analysis.

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Change From Baseline in Hemoglobin A1c at Week 26

    An ANCOVA model was used for the analysis.

    Time frame: Baseline, Week 26

  2. Change From Baseline in Body Weight at Week 26 and 52

    An ANCOVA model was used for the analysis.

    Time frame: Baseline, Week 26, Week 52

  3. Change From Baseline in Systolic Blood Pressure (SBP) for Participants With SBP ≥130 mmHg at Week 12

    An ANCOVA model was used for the analysis.

    Time frame: Baseline, Week 12

  4. Change From Baseline in Systolic Blood Pressure (SBP) for All Participants at Week 12

    An ANCOVA model was used for the analysis.

    Time frame: Baseline, Week 12

  5. Percentage of Participants With At Least One Documented Symptomatic Hypoglycemic Event

    Documented symptomatic hypoglycemia includes the typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L).

    Time frame: Up to Week 52

  6. Percentage of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Week 52

Other outcomes

  1. Percentage of Participants With Hypoglycemic Events

    Percentage of participants with hypoglycemic events are reported for the following 3 categories: Any hypoglycemia (as reported in the Electronic Case Report Form); Documented symptomatic hypoglycemia \[typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L)\]; Severe \[an event requiring assistance of another person to actively administer carbohydrate, glucagon, intravenous glucose or other resuscitative actions\] or documented symptomatic hypoglycemia \[typical symptoms of hypoglycemia and plasma glucose ≤ 70 mg/dL\].

    Time frame: Up to Week 52

07

Results

Posted May 11, 2021

Participant flow

Participants took part in the study at 138 investigative sites in United States, Bulgaria, Hungary, and Slovakia from 01 December 2017 to 06 September 2019.

Participant flow — Overall Study
MilestonePlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepiride
Started159317160318
Completed125266128270
Not completed34513248
Withdrew: Adverse event6413
Withdrew: Poor compliance to protocol0101
Withdrew: Lost to follow-up2212
Withdrew: At the participant's own request20261423
Withdrew: Reason not specified6181619

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c at Week 52

An analysis of covariance (ANCOVA) model was used for the analysis.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Hemoglobin A1c at Week 52
percentage of HbA1cPlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepiride
Change From Baseline in Hemoglobin A1c at Week 52-0.40 ± 0.187-0.65 ± 0.101-0.49 ± 0.114-0.61 ± 0.093
Statistical analysis
  • Sotagliflozin 400 mg vs Glimepiride · ANCOVA · p = 0.3306 · Difference in least squares (ls) mean: 0.12 · 95% CI -0.120 to 0.357
  • Sotagliflozin 200 mg vs Glimepiride · ANCOVA · p = 0.7112 · Difference in ls mean: -0.04 · 95% CI -0.265 to 0.181
SecondaryChange From Baseline in Hemoglobin A1c at Week 26

An ANCOVA model was used for the analysis.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Hemoglobin A1c at Week 26
percentage of HbA1cPlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepiride
Change From Baseline in Hemoglobin A1c at Week 26-0.41 ± 0.097-0.77 ± 0.076-0.61 ± 0.098-1.02 ± 0.075
Statistical analysis
  • Sotagliflozin 400 mg vs Glimepiride · ANCOVA · p = 0.0827 · Difference in ls mean: -0.21 · 95% CI -0.440 to 0.027
  • Sotagliflozin 200 mg vs Glimepiride · ANCOVA · p = 0.0003 · Difference in ls mean: -0.37 · 95% CI -0.571 to -0.167
SecondaryChange From Baseline in Body Weight at Week 26 and 52

An ANCOVA model was used for the analysis.

Time frame:
Baseline, Week 26, Week 52
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight at Week 26 and 52
kilogram (kg)PlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepiride
Change at Week 26-1.26 ± 0.329-2.75 ± 0.257-2.24 ± 0.3360.70 ± 0.256
Change at Week 52-0.47 ± 1.406-2.64 ± 0.503-1.74 ± 0.7070.94 ± 0.452
Statistical analysis
  • Placebo vs Sotagliflozin 400 mg · ANCOVA · p = <0.0001 · Difference in ls mean: -1.49 · 95% CI -2.173 to -0.803
  • Sotagliflozin 400 mg vs Glimepiride · ANCOVA · p = < 0.0001 · Difference in ls mean: -3.58 · 95% CI -4.651 to -2.517
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) for Participants With SBP ≥130 mmHg at Week 12

An ANCOVA model was used for the analysis.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Systolic Blood Pressure (SBP) for Participants With SBP ≥130 mmHg at Week 12
mmHgPlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepiride
Change From Baseline in Systolic Blood Pressure (SBP) for Participants With SBP ≥130 mmHg at Week 12-5.34 ± 1.451-8.03 ± 1.064-9.12 ± 1.466-3.86 ± 1.081
Statistical analysis
  • Sotagliflozin 400 mg vs Glimepiride · ANCOVA · p = 0.0012 · Difference in ls mean: -4.18 · 95% CI -6.701 to -1.650
  • Placebo vs Sotagliflozin 400 mg · ANCOVA · p = 0.0973 · Difference in ls mean: -2.70 · 95% CI -5.890 to 0.491
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) for All Participants at Week 12

An ANCOVA model was used for the analysis.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Systolic Blood Pressure (SBP) for All Participants at Week 12
mmHgPlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepiride
Change From Baseline in Systolic Blood Pressure (SBP) for All Participants at Week 12-2.64 ± 1.013-4.70 ± 0.791-4.77 ± 1.033-0.68 ± 0.795
Statistical analysis
  • Sotagliflozin 400 mg vs Glimepiride · ANCOVA · p = <0.0001 · Difference in ls mean: -4.02 · 95% CI -5.730 to -2.319
SecondaryPercentage of Participants With At Least One Documented Symptomatic Hypoglycemic Event

Documented symptomatic hypoglycemia includes the typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L).

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With At Least One Documented Symptomatic Hypoglycemic Event
percentage of participantsPlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepiride
Percentage of Participants With At Least One Documented Symptomatic Hypoglycemic Event0.631.263.7516.67
Statistical analysis
  • Sotagliflozin 400 mg vs Glimepiride · Cochran-Mantel-Haenszel · p = <0.0001 · Percentage difference: -15.4 · 95% CI -19.67 to -11.12
SecondaryPercentage of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsPlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepiride
Percentage of Participants With Adverse Events (AEs)57.259.956.649.2
Other pre-specifiedPercentage of Participants With Hypoglycemic Events

Percentage of participants with hypoglycemic events are reported for the following 3 categories: Any hypoglycemia (as reported in the Electronic Case Report Form); Documented symptomatic hypoglycemia \[typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L)\]; Severe \[an event requiring assistance of another person to actively administer carbohydrate, glucagon, intravenous glucose or other resuscitative actions\] or documented symptomatic hypoglycemia \[typical symptoms of hypoglycemia and plasma glucose ≤ 70 mg/dL\].

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Hypoglycemic Events
percentage of participantsPlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepiride
Any hypoglycemia2.54.16.325.9
Documented symptomatic hypoglycemia0.61.33.816.7
Severe or documented symptomatic hypoglycemia0.61.33.816.7

Adverse events

Collected over First dose of study drug to last dose of study drug (up to 52 weeks) + 2 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo2/159 (1.3%)11/159 (6.9%)30/159 (18.9%)
Sotagliflozin 400 mg1/317 (0.3%)17/317 (5.4%)49/317 (15.5%)
Sotagliflozin 200 mg0/159 (0%)11/159 (6.9%)21/159 (13.2%)
Glimepiride2/317 (0.6%)14/317 (4.4%)22/317 (6.9%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventPlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepiride
Non-cardiac chest painGeneral disorders2/1591/3170/1590/317
PneumoniaInfections and infestations0/1590/3171/1592/317
Acute left ventricular failureCardiac disorders1/1591/3170/1590/317
Angina pectorisCardiac disorders1/1590/3170/1590/317
Angina unstableCardiac disorders1/1590/3170/1590/317
Atrial fibrillationCardiac disorders0/1590/3171/1590/317
Supraventricular tachycardiaCardiac disorders1/1590/3170/1590/317
DeathGeneral disorders1/1590/3170/1590/317
Influenza like illnessGeneral disorders1/1590/3170/1590/317
CholelithiasisHepatobiliary disorders0/1590/3171/1590/317
Most frequent other events
Most frequent other events
EventPlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepiride
DiarrhoeaGastrointestinal disorders11/15914/3178/1597/317
HeadacheNervous system disorders11/15914/3177/15912/317
Vulvovaginal mycotic infectionInfections and infestations2/15919/3176/1592/317
HyperglycaemiaMetabolism and nutrition disorders8/1595/3172/1592/317

Baseline characteristics

The randomized population included any participant who had been allocated to a randomized treatment.

Age, Continuous
Age, Continuous(years)PlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepirideTotal
Mean58.8 ± 11.259.7 ± 10.458.6 ± 9.959.8 ± 9.659.4 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepirideTotal
Female7715775143452
Male8216085175502
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepirideTotal
Hispanic or Latino488553111297
Not Hispanic or Latino110230106207653
Unknown or Not Reported12104
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepirideTotal
American Indian or Alaska Native01012
Asian353415
Native Hawaiian or Other Pacific Islander11204
Black or African American13341936102
White141269136277823
More than one race13004
Unknown or Not Reported04004
Region of Enrollment
Region of Enrollment(participants)PlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepirideTotal
Bulgaria71751645
Hungary22482442136
Slovakia1228103080
United States118224121230693
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(percentage of HbA1c)PlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepirideTotal
Mean8.12 ± 0.738.09 ± 0.788.11 ± 0.868.07 ± 0.798.09 ± 0.79
Systolic Blood Pressure (SBP)
Systolic Blood Pressure (SBP)(millimeter of mercury (mmHg))PlaceboSotagliflozin 400 mgSotagliflozin 200 mgGlimepirideTotal
Mean133.23 ± 14.90133.17 ± 14.37132.78 ± 13.29134.66 ± 14.43133.61 ± 14.30
08

Study locations

142 sites
  • Investigational Site Number 8407040
    Birmingham, Alabama 35205, United States
  • Investigational Site Number 8407048
    Birmingham, Alabama 35233-2110, United States
  • Investigational Site Number 8407035
    Little Rock, Arkansas 72211, United States
  • Investigational Site Number 8407051
    Anaheim, California 92801-2417, United States
  • Investigational Site Number 8407065
    Canoga Park, California 91301, United States
  • Investigational Site Number 8407078
    Carmichael, California 95608, United States
  • Investigational Site Number 8407089
    Downey, California 90242, United States
  • Investigational Site Number 8407011
    Gold River, California 95670, United States
  • Investigational Site Number 8407044
    Greenbrae, California 94904, United States
  • Investigational Site Number 8407006
    Huntington Park, California 90255-2911, United States
  • Investigational Site Number 8407037
    Lemon Grove, California 91945, United States
  • Investigational Site Number 8407100
    Lomita, California 90717, United States
  • Investigational Site Number 8407033
    Long Beach, California 90806, United States
  • Investigational Site Number 8407019
    Los Angeles, California 90057-3507, United States
  • Investigational Site Number 8407098
    Northridge, California 91325-5409, United States
  • Investigational Site Number 8407094
    Norwalk, California 90650, United States
  • Investigational Site Number 8407106
    Pomona, California 91766, United States
  • Investigational Site Number 8407096
    Rancho Cucamonga, California 91730, United States
  • Investigational Site Number 8407036
    Sacramento, California 95821, United States
  • Investigational Site Number 8407084
    Tarzana, California 91356-3551, United States
  • Investigational Site Number 8407034
    Upland, California 91786-4070, United States
  • Investigational Site Number 8407032
    Van Nuys, California 91405, United States
  • Investigational Site Number 8407004
    Walnut Creek, California 94598, United States
  • Investigational Site Number 8407117
    Wildomar, California 92595, United States
  • Investigational Site Number 8407045
    Colorado Springs, Colorado 80920-8075, United States
  • Investigational Site Number 8407074
    Bradenton, Florida 34201, United States
  • Investigational Site Number 8407027
    Clearwater, Florida 33761, United States
  • Investigational Site Number 8407103
    Cooper City, Florida 33024, United States
  • Investigational Site Number 8407021
    Coral Gables, Florida 33134, United States
  • Investigational Site Number 8407062
    Lake Worth, Florida 33467, United States
  • Investigational Site Number 8407121
    Ocoee, Florida 34761, United States
  • Investigational Site Number 8407024
    Orlando, Florida 32825-4454, United States
  • Investigational Site Number 8407038
    Palmetto Bay, Florida 33157-5503, United States
  • Investigational Site Number 8407093
    Pembroke Pines, Florida 33026-3924, United States
  • Investigational Site Number 8407107
    Spring Hill, Florida 34609, United States
  • Investigational Site Number 8407091
    Tampa, Florida 33619, United States
  • Investigational Site Number 8407113
    Tampa, Florida 33634, United States
  • Investigational Site Number 8407092
    West Palm Beach, Florida 33401, United States
  • Investigational Site Number 8407115
    Winter Haven, Florida 33880, United States
  • Investigational Site Number 8407017
    Chicago, Illinois 60607, United States
  • Investigational Site Number 8407018
    Elgin, Illinois 60124, United States
  • Investigational Site Number 8407046
    Gurnee, Illinois 60031, United States
  • Investigational Site Number 8407119
    Springfield, Illinois 62711, United States
  • Investigational Site Number 8407075
    Waterloo, Iowa 50702, United States
  • Investigational Site Number 8407120
    West Des Moines, Iowa 50265, United States
  • Investigational Site Number 8407095
    Topeka, Kansas 66606-2806, United States
  • Investigational Site Number 8407083
    Wichita, Kansas 67205-1138, United States
  • Investigational Site Number 8407043
    Lexington, Kentucky 40503-2517, United States
  • Investigational Site Number 8407087
    Lexington, Kentucky 40503, United States
  • Investigational Site Number 8407060
    Lake Charles, Louisiana 70601, United States
  • Investigational Site Number 8407058
    New Orleans, Louisiana 70119, United States
  • Investigational Site Number 8407009
    New Orleans, Louisiana 70124, United States
  • Investigational Site Number 8407079
    Zachary, Louisiana 70791-4010, United States
  • Investigational Site Number 8407085
    Baltimore, Maryland 21237, United States
  • Investigational Site Number 8407001
    Rockville, Maryland 20852, United States
  • Investigational Site Number 8407069
    Troy, Michigan 48098-6334, United States
  • Investigational Site Number 8407110
    Olive Branch, Mississippi 38654, United States
  • Investigational Site Number 8407054
    Bridgeton, Missouri 63044, United States
  • Investigational Site Number 8407049
    Norfolk, Nebraska 68701, United States
  • Investigational Site Number 8407039
    Omaha, Nebraska 68114, United States
  • Investigational Site Number 8407061
    Papillion, Nebraska 68046-3136, United States
  • Investigational Site Number 8407108
    Las Vegas, Nevada 89106-4132, United States
  • Investigational Site Number 8407050
    Albuquerque, New Mexico 87106, United States
  • Investigational Site Number 8407116
    New York, New York 10016-6402, United States
  • Investigational Site Number 8407086
    New York, New York 10029, United States
  • Investigational Site Number 8407122
    New York, New York 10036, United States
  • Investigational Site Number 8407123
    West Seneca, New York 14224, United States
  • Investigational Site Number 8407020
    Greensboro, North Carolina 27408, United States
  • Investigational Site Number 8407114
    Lenoir, North Carolina 28645-8981, United States
  • Investigational Site Number 8407015
    Morehead City, North Carolina 28557, United States
  • Investigational Site Number 8407030
    Salisbury, North Carolina 28144-2742, United States
  • Investigational Site Number 8407041
    Wilmington, North Carolina 28401-6638, United States
  • Investigational Site Number 8407101
    Winston-Salem, North Carolina 27103, United States
  • Investigational Site Number 8407099
    Cincinnati, Ohio 45245, United States
  • Investigational Site Number 8407081
    Lyndhurst, Ohio 44124-2467, United States
  • Investigational Site Number 8407057
    Norman, Oklahoma 73069, United States
  • Investigational Site Number 8407073
    Oklahoma City, Oklahoma 73104-3252, United States
  • Investigational Site Number 8407068
    Eugene, Oregon 97404, United States
  • Investigational Site Number 8407104
    Beaver, Pennsylvania 15009-1957, United States
  • Investigational Site Number 8407025
    Hatboro, Pennsylvania 19040-2045, United States
  • Investigational Site Number 8407053
    Lansdale, Pennsylvania 19446-1002, United States
  • Investigational Site Number 8407016
    Charleston, South Carolina 29407, United States
  • Investigational Site Number 8407071
    Greer, South Carolina 29651-1817, United States
  • Investigational Site Number 8407022
    Mount Pleasant, South Carolina 29464, United States
  • Investigational Site Number 8407031
    Mount Pleasant, South Carolina 29464, United States
  • Investigational Site Number 8407014
    Jefferson City, Tennessee 37760, United States
  • Investigational Site Number 8407002
    Knoxville, Tennessee 37938, United States
  • Investigational Site Number 8407056
    Memphis, Tennessee 38163, United States
  • Investigational Site Number 8407026
    Austin, Texas 78735-8982, United States
  • Investigational Site Number 8407029
    Beaumont, Texas 77702, United States
  • Investigational Site Number 8407070
    Carrollton, Texas 75010, United States
  • Investigational Site Number 8407102
    Corpus Christi, Texas 78414-4173, United States
  • Investigational Site Number 8407023
    Dallas, Texas 75230, United States
  • Investigational Site Number 8407111
    Dallas, Texas 75231, United States
  • Investigational Site Number 8407013
    Fort Worth, Texas 76164, United States
  • Investigational Site Number 8407080
    Houston, Texas 77040, United States
  • Investigational Site Number 8407088
    Houston, Texas 77095-2856, United States
  • Investigational Site Number 8407090
    Katy, Texas 77450, United States
  • Investigational Site Number 8407042
    Lampasas, Texas 76550-1820, United States
  • Investigational Site Number 8407067
    Lufkin, Texas 75904, United States

Showing the first 100 of 142 sites across 4 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Aug 2019, 20 months.

Results were first posted in May 2021, 1 year 9 months after primary completion. A results delay was requested in May 2020.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2017
First posted
Nov 6, 2017
StartActual
Dec 1, 2017
Primary completionActual
Aug 6, 2019
CompletionActual
Sep 6, 2019
Results delay requested
May 1, 2020
Results first posted
May 11, 2021
Last update
May 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03332771
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Dec 1, 2017
Primary completion
Aug 6, 2019
Completion
Sep 6, 2019
Results posted
May 11, 2021
Last update
May 11, 2021

Study contacts

Suman Wason, MD
study director · Lexicon Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotagliflozin

Start the discussion